Azitra, Inc. Announces New U.S. Patent Protecting ATR-12 Program

Patent offers broad protections for ATR-12, an engineered strain of S. epidermidis that expresses a fragment of human LEKTI protein ATR-12 is currently the subject of a Phase 1b trial for the treatment of Netherton syndrome BRANFORD, Conn.